Luminex eyes $64.5m new capital
This article was originally published in Clinica
Executive Summary
Austin, Texas-based diagnostics company Luminex is looking to bag $64.5m in net proceeds from a public offering of 3.5 million new shares, priced at $19.91 per unit. The company, which developed the xMAP open-architecture, multi-analyte technology platform, intends to use the capital for general corporate purposes, which include R&D and potential acquisitions. The offering is expected to close June 30.